tradingkey.logo
tradingkey.logo
Search

NewGenIvf Group Ltd

NIVF
Add to Watchlist
0.461USD
-0.090-16.42%
Close 07/02, 13:00ETQuotes delayed by 15 min
16.53KMarket Cap
0.00P/E TTM

TradingKey Stock Score of NewGenIvf Group Ltd

Currency: USD Updated: 2026-07-02

Key Insights

NewGenIvf Group Ltd's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered undervalued, ranking 68 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is relatively high.Over the past month, multiple analysts have rated it as , with the highest price target at 14.12.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NewGenIvf Group Ltd's Score

Industry at a Glance

Industry Ranking
68 / 75
Overall Ranking
533 / 4565
Industry
Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

NewGenIvf Group Ltd Highlights

StrengthsRisks
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.73M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.73M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.51K shares, increasing 45.71% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.55.

Analyst Rating

Based on 0 analysts
--
Current Rating
14.120
Target Price
+2461.22%
Upside Space

FAQs

How does TradingKey generate the Stock Score of NewGenIvf Group Ltd?

The TradingKey Stock Score provides a comprehensive assessment of NewGenIvf Group Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of NewGenIvf Group Ltd’s performance and outlook.

How do we generate the financial health score of NewGenIvf Group Ltd?

To generate the financial health score of NewGenIvf Group Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects NewGenIvf Group Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of NewGenIvf Group Ltd.

How do we generate the company valuation score of NewGenIvf Group Ltd?

To generate the company valuation score of NewGenIvf Group Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare NewGenIvf Group Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of NewGenIvf Group Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of NewGenIvf Group Ltd.

How do we generate the earnings forecast score of NewGenIvf Group Ltd?

To calculate the earnings forecast score of NewGenIvf Group Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on NewGenIvf Group Ltd’s future.

How do we generate the price momentum score of NewGenIvf Group Ltd?

When generating the price momentum score for NewGenIvf Group Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of NewGenIvf Group Ltd’s prices. A higher score indicates a more stable short-term price trend for NewGenIvf Group Ltd.

How do we generate the institutional confidence score of NewGenIvf Group Ltd?

To generate the institutional confidence score of NewGenIvf Group Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about NewGenIvf Group Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of NewGenIvf Group Ltd.

How do we generate the risk management score of NewGenIvf Group Ltd?

To assess the risk management score of NewGenIvf Group Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of NewGenIvf Group Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of NewGenIvf Group Ltd.